SMA Capital’s Arcutis Biotherapeutics ARQT Stock Holding History

SMA Capital’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-239	Closed	-$5.63K	–	125
2026 Q1	$5.63K	Buy	+239	New	+$6.1K	﹤0.01%	84

Other funds holding ARQT

SCM

Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FLSM

Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return

RCMNY

Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return

PCH

Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

SMA Capital's ARQT Position: Q2 2026 in Review

SMA Capital sold out of Arcutis Biotherapeutics (ARQT) in Q2 2026, closing a stake of 239 shares — an estimated $5.63K sold.

SMA Capital first reported a position in ARQT in Q1 2026 and held it in 1 quarter. The position peaked at $5.63K in Q1 2026. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

SMA Capital reported no remaining Arcutis Biotherapeutics position as of Q2 2026 after selling out during the quarter.
SMA Capital sold 239 Arcutis Biotherapeutics shares in Q2 2026, an estimated $5.63K.
SMA Capital first reported a position in Arcutis Biotherapeutics in Q1 2026 and held it in 1 quarter.
SMA Capital's Arcutis Biotherapeutics position peaked at $5.63K in Q1 2026.
272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on SMA Capital's 13F filing for Q2 2026, filed 14 Aug 2026.